International Journal of Autism
2022, Vol. 2, Issue 1, Part A
A review of the use of transcranial magnetic stimulation in neurology
Author(s): Hani Raoul Khouzam
Abstract: Transcranial Magnetic Stimulation (TMS) has been approved by the US Food and Drug Administration (FDA) for the treatment and prevention of severe migraine headaches. Preliminary studies have documented its potential therapeutic benefits in several neurologic diseases. This review, summarizes some of the preliminary studies exploring the potential therapeutic use of TMS for several neurologic disorders such as headaches associated with mild traumatic brain injury, epilepsy, chronic pain, pain associated with fibromyalgia, post –stroke aphasia, spastic cerebral palsy, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, dystonia, and Huntington's disease.. The efficacy of TMS in treating these conditions is still anecdotal and would require larger randomized placebo controlled sample population, to confirm this minimally invasive and relatively safe brain stimulation technique, as a standard treatment for the neurologic disorders that do not respond to their currently approved clinical interventions.
Pages: 06-10 | Views: 170 | Downloads: 54
Download Full Article: Click Here
How to cite this article:
Hani Raoul Khouzam. A review of the use of transcranial magnetic stimulation in neurology. International Journal of Autism. 2022; 2(1): 06-10.